Immunovant (IMVT) News Today $18.19 -1.25 (-6.43%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$18.79 +0.60 (+3.30%) As of 03/25/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Knights of Columbus Asset Advisors LLC Takes $616,000 Position in Immunovant, Inc. (NASDAQ:IMVT)Knights of Columbus Asset Advisors LLC acquired a new stake in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 24,873 shares of theMarch 24 at 5:43 AM | marketbeat.comBank of America Cuts Immunovant (NASDAQ:IMVT) Price Target to $33.00March 23 at 3:07 AM | americanbankingnews.comImmunovant's (IMVT) "Buy" Rating Reiterated at GuggenheimMarch 23 at 3:07 AM | americanbankingnews.comImmunovant (NASDAQ:IMVT) Earns Buy Rating from HC WainwrightMarch 22, 2025 | americanbankingnews.comLeerink Partners Reaffirms Their Buy Rating on Immunovant (IMVT)March 21, 2025 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Shares Up 3.9% - Time to Buy?Immunovant (NASDAQ:IMVT) Stock Price Up 3.9% - Here's What HappenedMarch 21, 2025 | marketbeat.comGuggenheim Reiterates "Buy" Rating for Immunovant (NASDAQ:IMVT)Guggenheim reissued a "buy" rating on shares of Immunovant in a research note on Thursday.March 21, 2025 | marketbeat.comBank of America Has Lowered Expectations for Immunovant (NASDAQ:IMVT) Stock PriceBank of America lowered their price objective on Immunovant from $38.00 to $33.00 and set a "buy" rating for the company in a research report on Thursday.March 21, 2025 | marketbeat.comImmunovant price target lowered to $33 from $38 at BofAMarch 21, 2025 | markets.businessinsider.comImmunovant price target raised to $61 from $58 at StifelMarch 21, 2025 | markets.businessinsider.comHC Wainwright Reaffirms "Buy" Rating for Immunovant (NASDAQ:IMVT)HC Wainwright reiterated a "buy" rating and issued a $51.00 price target on shares of Immunovant in a research note on Wednesday.March 20, 2025 | marketbeat.comImmunovant data positive for Biohaven, says Deutsche BankMarch 20, 2025 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Hits New 1-Year Low - Here's WhyImmunovant (NASDAQ:IMVT) Hits New 12-Month Low - Time to Sell?March 20, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. reduced its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 86.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,100 shares of the company's stock after sMarch 20, 2025 | marketbeat.comImmunovant’s batoclimab shows ‘impressive’ efficacy in MG, says H.C. WainwrightMarch 20, 2025 | markets.businessinsider.comImmunovant announces results from Phase 3 study of batoclimab in MGMarch 19, 2025 | markets.businessinsider.comImmunovant claims study success for immune disease drug but holds off on submissionMarch 19, 2025 | finance.yahoo.comImmunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going ForwardMarch 19, 2025 | seekingalpha.comImmunovant's muscle drug meets main goal, shares gain on new drug promiseMarch 19, 2025 | msn.comImmunovant will not seek approval for MG therapy, despite hitting endpointsMarch 19, 2025 | finance.yahoo.comRoivant says Immunovant announces results from Phase 3 study of batoclimab in MGMarch 19, 2025 | markets.businessinsider.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)March 19, 2025 | prnewswire.comRoivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.March 19, 2025 | investors.comImmunovant stock falls despite study successMarch 19, 2025 | investing.comImmunovant, Roivant slip after trial data for autoimmune disorder therapyMarch 19, 2025 | msn.comImmunovant's muscle disorder treatment meets main goal in late-stage trialMarch 19, 2025 | reuters.comImmunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) StudiesMarch 19, 2025 | globenewswire.comImmunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ProgramsMarch 18, 2025 | globenewswire.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by Skandinaviska Enskilda Banken AB publSkandinaviska Enskilda Banken AB publ trimmed its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 60.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 35,316 shares of the company's stock after selMarch 18, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Connor Clark & Lunn Investment Management Ltd. raised its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 29.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 235,884 shares of the company's stock after purchasing an addiMarch 16, 2025 | marketbeat.comAndrew J. Fromkin Sells 8,000 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) Director Andrew J. Fromkin sold 8,000 shares of Immunovant stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $19.60, for a total value of $156,800.00. Following the sale, the director now owns 91,913 shares in the company, valued at $1,801,494.80. This represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.March 12, 2025 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Director Andrew J. Fromkin Sells 8,000 SharesMarch 12, 2025 | insidertrades.comGuggenheim Reiterates Buy Rating for Immunovant (NASDAQ:IMVT)Guggenheim restated a "buy" rating on shares of Immunovant in a report on Monday.March 11, 2025 | marketbeat.comCantor Fitzgerald Comments on Immunovant FY2025 EarningsImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Immunovant in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($1.88) per shareMarch 7, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Upgraded by Cantor Fitzgerald to Strong-Buy RatingCantor Fitzgerald upgraded shares of Immunovant to a "strong-buy" rating in a research note on Tuesday.March 6, 2025 | marketbeat.comImmunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | insidermonkey.comImmunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending RecentlyMarch 5, 2025 | msn.comImmunovant, Inc. (NASDAQ:IMVT) Given Average Rating of "Moderate Buy" by BrokeragesShares of Immunovant, Inc. (NASDAQ:IMVT - Get Free Report) have received a consensus rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, ten have given a bMarch 4, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Hits New 52-Week Low - Time to Sell?Immunovant (NASDAQ:IMVT) Hits New 12-Month Low - Time to Sell?March 4, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Stock Price Down 8.3% - What's Next?Immunovant (NASDAQ:IMVT) Trading Down 8.3% - Here's WhyMarch 3, 2025 | marketbeat.comImmunovant (NASDAQ:IMVT) Now Covered by Analysts at Jefferies Financial GroupJefferies Financial Group assumed coverage on Immunovant in a research report on Monday. They issued a "hold" rating and a $20.00 target price on the stock.March 3, 2025 | marketbeat.comFY2025 EPS Estimates for Immunovant Cut by Zacks ResearchImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities researchers at Zacks Research reduced their FY2025 earnings estimates for shares of Immunovant in a research report issued on Wednesday, February 26th. Zacks Research analyst E. Bagri now forecasts that the company will post earnings of ($2.March 3, 2025 | marketbeat.comImmunovant initiated with a Hold at JefferiesMarch 2, 2025 | markets.businessinsider.comImmunovant FY2025 EPS Estimate Lowered by Lifesci CapitalImmunovant, Inc. (NASDAQ:IMVT - Free Report) - Lifesci Capital dropped their FY2025 earnings estimates for Immunovant in a report released on Sunday, February 23rd. Lifesci Capital analyst S. Slutsky now expects that the company will earn ($2.64) per share for the year, down from their previous eFebruary 26, 2025 | marketbeat.comPrincipal Financial Group Inc. Lowers Stake in Immunovant, Inc. (NASDAQ:IMVT)Principal Financial Group Inc. cut its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 16.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 791,863 shares of the company's stock after sellinFebruary 25, 2025 | marketbeat.comImmunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to AnalystsFebruary 23, 2025 | insidermonkey.comImmunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?February 22, 2025 | insidermonkey.comStifel Nicolaus Remains a Buy on Immunovant (IMVT)February 21, 2025 | markets.businessinsider.comImmunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On RecentlyFebruary 20, 2025 | insidermonkey.comABC Arbitrage SA Invests $734,000 in Immunovant, Inc. (NASDAQ:IMVT)ABC Arbitrage SA bought a new position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 29,639 shares of the company's stock, valued at appFebruary 16, 2025 | marketbeat.com Remove Ads Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼0.360.79▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼315▲IMVT Articles Average Week Remove Ads Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News Today GMAB News Today RDY News Today VTRS News Today ASND News Today PCVX News Today QGEN News Today ROIV News Today SRPT News Today RVMD News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMVT Stock Free IMVT Stock Alerts